Sekar Kathiresan (Verve)
January 12, 2021 07:10 AM ESTUpdated 07:28 AM
R&D
Discovery

Look­ing to leapfrog an­ti­bod­ies and RNAi, Sekar Kathire­san says gene edit­ing ap­proach to cut PC­SK9 looks durable

Amber Tong

JP Mor­gan isn’t typ­i­cal­ly a da­ta con­fer­ence. But there are al­ways ex­cep­tions for da­ta that could make or break a com­pa­ny, piquing the in­ter­est of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Can Bill An­der­son save Bay­er?

Verve is lat­est gene edit­ing com­pa­ny to suf­fer set­back, as Ver­tex walks away from pact

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

Drug pol­i­cy vet­er­an at CMS to de­part on Fri­day

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times